XML 72 R65.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Loss per Share - Schedule of Potentially Dilutive Shares Were Not Included In The Calculation of Diluted Shares Outstanding (Details) - shares | 6 Months Ended
--- | ---
Jun. 30, 2024 | Jun. 30, 2023
Performance stock units |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 2,676,300 | 6,690,750
DRSUs |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 4,276,875 | 3,637,905
Options |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 73,698,315 | 64,289,090
Restricted stock units |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 2,640,115 | 2,738,750
Convertibale loan notes | Private Placement Loan Notes [Member] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 0 | 24,279,659
Convertibale loan notes | Novartis [Member] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 16,308,364 | 15,000,137
Warrants to purchase ordinary shares |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 7,539,129 | 7,539,129
AstraZeneca milestones potentially payable in equity |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 1,349,692 | 1,349,692

X
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=mreo_DeferredRestrictedStockUnitsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=mreo_NovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mreo_MilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |